Eosinophil and mast cell Siglecs: From biology to drug target

Jeremy A. O'Sullivan*, Alan T. Chang, Bradford A. Youngblood, Bruce S. Bochner

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

33 Scopus citations


Mast cells and eosinophils are innate immune cells involved in both acute and chronic inflammatory responses. Siglecs are a family of cell surface receptors that share sialic acid binding activity. Over the past 20 years, our knowledge of the expression and function of Siglecs on cells of the immune system and others has greatly expanded, as has our understanding of their signaling, ligands, and possible roles in disease pathophysiology. Because of this, Siglecs have garnered interest as potential drug targets using strategies ranging from biologics to ligand-directed nanoparticles. This mini-review will highlight the state of our knowledge regarding human eosinophil and mast cell Siglecs, their biology, what they recognize, tools developed for in vitro and preclinical experimentation, and the status of ongoing efforts to develop drugs that engage eosinophil and mast cell Siglecs for potential therapeutic benefit.

Original languageEnglish (US)
Pages (from-to)73-81
Number of pages9
JournalJournal of Leukocyte Biology
Issue number1
StatePublished - Jul 1 2020


  • AK002
  • Siglec
  • antolimab
  • eosinophils
  • ligands
  • mast cells
  • signaling

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Cell Biology


Dive into the research topics of 'Eosinophil and mast cell Siglecs: From biology to drug target'. Together they form a unique fingerprint.

Cite this